Amarantus Bioscience Holdings Inc (AMBS)

[PENNYS ToMILLIONS]

“The fundamental progress the Company has made since our First Annual CEO Letter was released in May has been quite significant. We have achieved the following milestones:
1. Positive animal proof-of concept data for MANF in the multi-billion dollar Myocardial Infarction market;

Acute Myocardial Infarction
Approximately 800,000 events of acute myocardial infarction occur in the US each year and, despite all of the advances in medicine and intervention, about 20% or approximately 160,000 patients have a ST-Elevation MI (STEMI) resulting in a reduced Left Ventricular Ejection Fraction (LVEF) of less than 50%. That means that their MI was big enough and their heart so damaged that the remaining heart muscle could not compensate for the damaged heart tissues and, over time, the hearts starts to fail. These patients are at significant risk of downstream adverse events including congestive heart failure, re-current MI, significant arrhythmias, premature death or acute coronary syndrome

2. Secured the license for the NuroPro Parkinson’s diagnostic blood test; and

3. Successfully concluded our research collaboration with Banyan Biomarkers, showing positive proof-of concept data for MANF in Traumatic Brain Injury

Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
http://www.businesswire.com/news/home/20101005005193/en/Banyan-Biomarkers-Awarded-26.3-Million-Department-Defense